| Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. | |
| | |
MedLine Citation:
|
PMID: 19882303 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The management of patients with supra-therapeutic INR in a common clinical problem. The risk of bleeding is influenced by the intensity, variability and duration of anticoagulation, patient age, presence of co-morbidities and concomitant drug therapy. For the asymptomatic patient, warfarin discontinuation is all that is usually required but for individuals at high risk of bleeding and those with INR > 10, oral vitamin K administration is recommended. In the presence of major bleeding, treatment with intravenous vitamin K and prothrombin complex concentrate is the most effective therapy. |
| | |
Authors:
|
Michael Makris; Joost J van Veen; Rhona Maclean |
Related Documents
:
|
6691723 - The influence of prophylactic antibiotics on the warfarin anticoagulation response in t... 9684793 - Control of oral anticoagulation in patients with the antiphospholipid syndrome--influen... 15825973 - Alcohol use and adherence to prescribed therapy among under-served latino and african-a... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of thrombosis and thrombolysis Volume: 29 ISSN: 1573-742X ISO Abbreviation: J. Thromb. Thrombolysis Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-01-29 Completed Date: 2010-04-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9502018 Medline TA: J Thromb Thrombolysis Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 171-81 Citation Subset: IM |
Affiliation:
|
Sheffield Haemophilia and Thrombosis Centre, University of Sheffield, Sheffield, UK. m.makris@sheffield.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Anticoagulants / administration & dosage, adverse effects* Blood Coagulation / drug effects* Blood Coagulation Factors / administration & dosage Coagulants / administration & dosage*, adverse effects Drug Administration Schedule Evidence-Based Medicine Factor VIIa / administration & dosage Hemorrhage / blood, chemically induced, drug therapy* Humans Injections, Intravenous Injections, Subcutaneous International Normalized Ratio Practice Guidelines as Topic Recombinant Proteins / administration & dosage Risk Assessment Risk Factors Treatment Outcome Vitamin K / administration & dosage Warfarin / administration & dosage, adverse effects* |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Blood Coagulation Factors; 0/Coagulants; 0/Recombinant Proteins; 0/recombinant FVIIa; 12001-79-5/Vitamin K; 37224-63-8/prothrombin complex concentrates; 81-81-2/Warfarin; EC 3.4.21.21/Factor VIIa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Bifidobacterium longum HY8004 attenuates TNBS-induced colitis by inhibiting lipid peroxidation in mi...
Next Document: Modelling Young's modulus for porous bones with microstructural variation and anisotropy.